The growing prevalence of obesity presents a significant challenge globally, impacting individuals physically and mentally. In Slovakia, the National Institute for Health Evaluation and Technology (NIHO) has recommended the inclusion of the intragastric balloon system ORBERA365 in the reimbursable list of special medical materials. This recommendation targets patients who struggle to achieve weight loss through lifestyle changes, as well as those needing preoperative weight reduction. The objective is to address a gap in available medical interventions and offer a less invasive alternative before surgical procedures.
The focus on obesity management has intensified due to the increasing incidence of related health issues like type 2 diabetes and cardiovascular diseases. Current guidelines emphasize lifestyle modifications, pharmacological interventions, and in severe cases, bariatric surgery. However, for many, invasive surgery is not an ideal option. The ORBERA365 system, an intragastric balloon, provides a non-surgical alternative by filling the stomach partly to promote weight loss. Deployed via endoscopy, the balloon can remain in the stomach for 6 to 12 months, aiding patients in shedding excess weight.
Clinical and Economic Evaluations
Extensive evaluations of ORBERA365 demonstrated mixed results in weight loss effectiveness compared to laparoscopic sleeve gastrectomy (LSG), while showing a favorable safety profile. The system showed a total body weight loss of 15.38% after 12 months, which falls short compared to 28.9% observed post-LSG. Despite lower weight loss percentages, ORBERA365 offers the advantage of being less invasive and thus preferred for patients who either cannot undergo or wish to avoid invasive surgery.
Financial Viability and Implications
The economic analysis indicates ORBERA365 incurs lower costs compared to LSG. A NIHO evaluation calculated operational costs of the balloon system to be €2,795.11, significantly less than the €7,200.70 associated with LSG. Nevertheless, the determination of cost-effectiveness is complicated by uncertainties in the fiscal impact related to reimbursement structures and potential long-term budget increases as hospitals adjust to covering these technologies under simpler accounting categories.
Key takeaways from evaluations include:
- The balloon provides an intermediary intervention for weight loss between lifestyle modifications and major surgery.
- The system’s simplistic deployment allows broader access to weight loss solutions.
- Despite lower average weight loss, its minimally invasive nature could attract wider acceptance.
- Economic uncertainties stem from the intricate link between device cost, procedural settings, and healthcare funding models.
With NIHO’s approval of ORBERA365, Slovak patients may soon access a significant non-surgical weight loss tool. Although procedural cost comparisons with traditional surgical approaches favor the balloon, healthcare providers and policymakers must consider a myriad of financial challenges. Looking ahead, it is essential that strategies incorporate comprehensive policies accommodating multidimensional health needs alongside evolving technological solutions. Integrating patient education on potential outcomes and clear insurance billing practices will be pivotal to successful implementation and widespread utilization of this innovative approach. ORBERA365 represents a step toward more adaptable obesity management, yet stresses the enduring need for strategic, multidisciplinary engagement in public health solutions.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
